Vir Biotechnology Doses First Expansion Cohort Patient in Phase 1 Metastatic Prostate Cancer Trial
Vir Biotechnology (VIR) said Monday it has dosed the first patient in one of three expansion cohorts in a phase 1 trial assessing safety, pharmacokinetics and efficacy of VIR-5500 in metastatic prostate cancer.The company said the monotherapy expansion cohort in late-line metastatic castration-resistant prostate cancer is the first to begin enrollment.Vir said it expects to dose the first patients in the dose-expansion cohorts to evaluate VIR-5500 combined with an androgen receptor pathway inhibitor in early-line metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer, in the coming months.The company said it expects to launch pivotal phase 3 trials in 2027.Shares of Vir Biotechnology were down 1% in Monday trading.Price: $9.40, Change: $-0.10, Percent Change: -1.05%
